These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 11020195

  • 1. Diagnostic value of Epstein-Barr viral serology in nasopharyngeal carcinoma.
    Low WK, Leong JL, Goh YH, Fong KW.
    Otolaryngol Head Neck Surg; 2000 Oct; 123(4):505-7. PubMed ID: 11020195
    [Abstract] [Full Text] [Related]

  • 2. Complementary serum test of antibodies to Epstein-Barr virus nuclear antigen-1 and early antigen: a possible alternative for primary screening of nasopharyngeal carcinoma.
    Chang KP, Hsu CL, Chang YL, Tsang NM, Chen CK, Lee TJ, Tsao KC, Huang CG, Chang YS, Yu JS, Hao SP.
    Oral Oncol; 2008 Aug; 44(8):784-92. PubMed ID: 18206420
    [Abstract] [Full Text] [Related]

  • 3. Evaluation of commercial EBV RecombLine assay for diagnosis of nasopharyngeal carcinoma.
    Paramita DK, Fachiroh J, Haryana SM, Middeldorp JM.
    J Clin Virol; 2008 Aug; 42(4):343-52. PubMed ID: 18455473
    [Abstract] [Full Text] [Related]

  • 4. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY, Li YH, Gao HY, Wu QL, Cui NJ, Zhang L, Cheng G, Hu LF, Ernberg I, Zeng YX.
    Cancer; 2004 Mar 15; 100(6):1162-70. PubMed ID: 15022282
    [Abstract] [Full Text] [Related]

  • 5. The reliability of IgA antibody to Epstein-Barr virus (EBV) capsid antigen as a test for the diagnosis of nasopharyngeal carcinoma (NPC).
    Levine PH, Pearson GR, Armstrong M, Bengali Z, Berenberg J, Easton J, Goepfert H, Henle G, Henle W, Heffner D, Huang A, Hyams VJ, Lanier A, Neel HB, Pilch B, Pointek N, Taylor W, Terebelo H, Weiland L.
    Cancer Detect Prev; 1981 Mar 15; 4(1-4):307-12. PubMed ID: 6299561
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Significance of cell-free Epstein-Barr virus DNA in monitoring prognosis of nasopharyngeal carcinoma].
    Cao SM, Min HQ, Gao JS, Hong MH, Xiao XB, Zhang CQ, Liu XD, Zhang AL, Guo X.
    Ai Zheng; 2003 Mar 15; 22(3):302-6. PubMed ID: 12654192
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Comparison of three different serological techniques for primary diagnosis and monitoring of nasopharyngeal carcinoma in two age groups from Tunisia.
    Karray H, Ayadi W, Fki L, Hammami A, Daoud J, Drira MM, Frikha M, Jlidi R, Middeldorp JM.
    J Med Virol; 2005 Apr 15; 75(4):593-602. PubMed ID: 15714486
    [Abstract] [Full Text] [Related]

  • 10. Native early antigen of Epstein-Barr virus, a promising antigen for diagnosis of nasopharyngeal carcinoma.
    Paramita DK, Fachiroh J, Artama WT, van Benthem E, Haryana SM, Middeldorp JM.
    J Med Virol; 2007 Nov 15; 79(11):1710-21. PubMed ID: 17854043
    [Abstract] [Full Text] [Related]

  • 11. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN, Tang AZ, Zhou L, Huang GW, Wang Z, Zeng Y.
    Chin Med J (Engl); 2009 May 20; 122(10):1173-8. PubMed ID: 19493466
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Nasopharyngeal carcinoma: the diagnostic value of the antibody-dependent, cellular cytotoxicity test and of EBV serology.
    Faggioni A, Corradini C, Venanzoni M, Cardi G, Bevere F, Barile G, Zompetta C, Frati L.
    J Exp Pathol; 1987 May 20; 3(4):471-7. PubMed ID: 2842480
    [Abstract] [Full Text] [Related]

  • 17. Sensitivity and specificity of Epstein-Barr virus IGA titer in the diagnosis of nasopharyngeal carcinoma: a three-year institutional review.
    Tsang RK, Vlantis AC, Ho RW, Tam JS, To KF, van Hasselt CA.
    Head Neck; 2004 Jul 20; 26(7):598-602. PubMed ID: 15229902
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparison of Epstein-Barr Virus Serological Tools for the Screening and Risk Assessment of Nasopharyngeal Carcinoma: a Large Population-based Study.
    Guo J, Cui Z, Zheng Y, Li X, Chen Y.
    Pathol Oncol Res; 2020 Oct 20; 26(4):2185-2190. PubMed ID: 32222897
    [Abstract] [Full Text] [Related]

  • 20. Plasma Epstein-Barr virus immunoglobulin A and DNA for nasopharyngeal carcinoma screening in the United States.
    O TM, Yu G, Hu K, Li JC.
    Otolaryngol Head Neck Surg; 2007 Jun 20; 136(6):992-7. PubMed ID: 17547994
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.